Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO RegistryEmanuela Vaccher, Maria Mercedes Santoro, Maurizio Zazzi et al.|Open Forum Infectious Diseases|2020Cited by 51
A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study)Cristina Mussini, Franco Maggiolo, Enrica Roncaglia et al.|PLoS ONE|2019Cited by 16
Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfectionLE Weimer, Vincenzo Fragola, Marco Floridia et al.|Journal of Antimicrobial Chemotherapy|2012Cited by 10
Rate and Determinants of Residual Viremia in Multidrug-Experienced Patients Successfully Treated with Raltegravir-Based RegimensSilvia Baroncelli, Marco Floridia, Maria Franca Pirillo et al.|AIDS Research and Human Retroviruses|2014Cited by 10
Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factorsRaffaella Bucciardini, Marco Floridia, Gabriella d’Ettorre et al.|International Journal of STD & AIDS|2012Cited by 10